Characteristics of 199 patients with DLBCL and their associations with IL-10 serum levels in 149 patients who provided samples available for ELISA at the time of initial presentation
Characteristics . | All patients, n (%) . | Patients with an IL-10 level less than 5 pg/mL, n (%) . | Patients with an IL-10 level 5 pg/mL or greater, n (%) . | P* . |
|---|---|---|---|---|
| Sex | NS | |||
| Female | 104 (52) | 63 (54) | 16 (50) | |
| Male | 95 (48) | 54 (46) | 16 (50) | |
| Age | .01 | |||
| 60 y or younger | 104 (52) | 65 (56) | 9 (28) | |
| Older than 60 y | 95 (48) | 52 (44) | 23 (72) | |
| Performance status (ECOG) | .001 | |||
| Less than 2 | 137 (69) | 89 (76) | 16 (50) | |
| 2 or more | 54 (27) | 21 (18) | 16 (50) | |
| Unknown | 8 | 7 | ||
| B symptoms | .0004 | |||
| Absent | 141 (71) | 94 (80) | 15 (47) | |
| Present | 58 (29) | 23 (20) | 17 (53) | |
| Ann Arbor stage | .007 | |||
| I, II | 78 (39) | 51 (43) | 6 (19) | |
| III, IV | 110 (55) | 57 (49) | 26 (81) | |
| Unknown | 11 | 9 | ||
| Serum LDH | .005 | |||
| 1 × or less than normal | 77 (39) | 56 (48) | 7 (22) | |
| Greater than 1 × normal | 106 (53) | 49 (42) | 24 (75) | |
| Unknown | 16 | 12 | 1 | |
| Serum β2-microglobulin | < .0001 | |||
| 3.0 mg/L or less | 125 (63) | 81 (69) | 12 (37.5) | |
| Greater than 3.0 mg/L | 50 (25) | 20 (17) | 20 (62.5) | |
| Unknown | 24 | 16 | ||
| No of extranodal sites | NS | |||
| Less than 2 | 116 (58) | 71 (61) | 16 (50) | |
| 2 or more | 67 (34) | 35 (30) | 13 (41) | |
| Unknown | 16 | 11 | 3 | |
| Serum albumin level | < .0001 | |||
| 35 g/L or less | 53 (27) | 30 (26) | 22 (69) | |
| 35 g/L or greater | 123 (62) | 74 (63) | 8 (25) | |
| Unknown | 23 | 13 | 2 | |
| Hemoglobin | .03 | |||
| 120 g/L or less | 87 (44) | 47 (40) | 21 (66) | |
| Greater than 120 g/L | 99 (50) | 59 (50) | 11 (34) | |
| Unknown | 13 | 11 | ||
| Bulky tumor (10 cm or greater) | NS | |||
| Absent | 111 (56) | 65 (55) | 13 (41) | |
| Present | 77 (39) | 43 (37) | 18 (56) | |
| Unknown | 11 | 9 | 1 | |
| Complete remission rate | .0005 | |||
| Yes | 148 (74) | 96 (82) | 16 (50) | |
| No | 51 (26) | 21 (18) | 16 (50) | |
| International Prognostic Index risk groups | .003 | |||
| Low/intermediate low | 96 (48) | 64 (55) | 8 (25) | |
| Intermediate high/high | 79 (40) | 39 (33) | 20 (62) | |
| Unknown | 24 | 14 | 4 |
Characteristics . | All patients, n (%) . | Patients with an IL-10 level less than 5 pg/mL, n (%) . | Patients with an IL-10 level 5 pg/mL or greater, n (%) . | P* . |
|---|---|---|---|---|
| Sex | NS | |||
| Female | 104 (52) | 63 (54) | 16 (50) | |
| Male | 95 (48) | 54 (46) | 16 (50) | |
| Age | .01 | |||
| 60 y or younger | 104 (52) | 65 (56) | 9 (28) | |
| Older than 60 y | 95 (48) | 52 (44) | 23 (72) | |
| Performance status (ECOG) | .001 | |||
| Less than 2 | 137 (69) | 89 (76) | 16 (50) | |
| 2 or more | 54 (27) | 21 (18) | 16 (50) | |
| Unknown | 8 | 7 | ||
| B symptoms | .0004 | |||
| Absent | 141 (71) | 94 (80) | 15 (47) | |
| Present | 58 (29) | 23 (20) | 17 (53) | |
| Ann Arbor stage | .007 | |||
| I, II | 78 (39) | 51 (43) | 6 (19) | |
| III, IV | 110 (55) | 57 (49) | 26 (81) | |
| Unknown | 11 | 9 | ||
| Serum LDH | .005 | |||
| 1 × or less than normal | 77 (39) | 56 (48) | 7 (22) | |
| Greater than 1 × normal | 106 (53) | 49 (42) | 24 (75) | |
| Unknown | 16 | 12 | 1 | |
| Serum β2-microglobulin | < .0001 | |||
| 3.0 mg/L or less | 125 (63) | 81 (69) | 12 (37.5) | |
| Greater than 3.0 mg/L | 50 (25) | 20 (17) | 20 (62.5) | |
| Unknown | 24 | 16 | ||
| No of extranodal sites | NS | |||
| Less than 2 | 116 (58) | 71 (61) | 16 (50) | |
| 2 or more | 67 (34) | 35 (30) | 13 (41) | |
| Unknown | 16 | 11 | 3 | |
| Serum albumin level | < .0001 | |||
| 35 g/L or less | 53 (27) | 30 (26) | 22 (69) | |
| 35 g/L or greater | 123 (62) | 74 (63) | 8 (25) | |
| Unknown | 23 | 13 | 2 | |
| Hemoglobin | .03 | |||
| 120 g/L or less | 87 (44) | 47 (40) | 21 (66) | |
| Greater than 120 g/L | 99 (50) | 59 (50) | 11 (34) | |
| Unknown | 13 | 11 | ||
| Bulky tumor (10 cm or greater) | NS | |||
| Absent | 111 (56) | 65 (55) | 13 (41) | |
| Present | 77 (39) | 43 (37) | 18 (56) | |
| Unknown | 11 | 9 | 1 | |
| Complete remission rate | .0005 | |||
| Yes | 148 (74) | 96 (82) | 16 (50) | |
| No | 51 (26) | 21 (18) | 16 (50) | |
| International Prognostic Index risk groups | .003 | |||
| Low/intermediate low | 96 (48) | 64 (55) | 8 (25) | |
| Intermediate high/high | 79 (40) | 39 (33) | 20 (62) | |
| Unknown | 24 | 14 | 4 |
Populations are as follows: all patients, n = 199; patients with IL-10 < 5 pg/mL, n = 117; and Patients with IL-10 ≥ 5 pg/mL, n = 32. NS denotes not significant.
The associations were compared with χ2 test.